Mylan's most recent trend suggests a bearish bias. One trading opportunity on Mylan is a Bear Call Spread using a strike $32.50 short call and a strike $37.50 long call offers a potential 5.49% return on risk over the next 27 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $32.50 by expiration. The full premium credit of $0.26 would be kept by the premium seller. The risk of $4.74 would be incurred if the stock rose above the $37.50 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Mylan is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Mylan is bearish.
The RSI indicator is below 20 which suggests that the stock is in oversold territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Mylan
[$$] Mylan Settles EpiPen Medicaid Overcharge Claims for $465 Million
Fri, 18 Aug 2017 04:18:42 +0000
Mylan agreed to pay $465 million to settle federal government claims that it overcharged the Medicaid program by millions of dollars for its EpiPen products.
U.S. House Democrats launch probe into MS drug pricing
Thu, 17 Aug 2017 21:38:58 +0000
U.S. House Democrats said on Thursday they were launching an investigation into why prices for Multiple Sclerosis (MS) treatments have nearly quintupled since 2004, and they sent letters requesting information from seven drugmakers. U.S. Representatives Elijah Cummings and Peter Welch sent the letters to Bayer AG, Biogen Inc, Merck KGaA's EMD Serono unit, Novartis AG, Roche Holding AG, Sanofi SA, and Teva Pharmaceutical Industries Inc .
Ohio to share in $465M settlement with EpiPen maker Mylan
Thu, 17 Aug 2017 20:40:15 +0000
Ohio will share in a $465 million settlement with EpiPen manufacturer Mylan Inc. Ohio Attorney General Mike DeWine announced today that Ohio has agreed in principle to join the United States and other States to settle allegations against Mylan Inc. and its wholly-owned subsidiary, Mylan Specialty L.P. The settlement will resolve allegations that Mylan knowingly underpaid rebates owed to the Medicaid program for the drugs EpiPen and EpiPen Jr. dispensed to Medicaid beneficiaries, according to the statement from DeWine.
EpiPen maker finalizes settlement for government overcharges
Thu, 17 Aug 2017 20:24:14 +0000
TRENTON, N.J. (AP) — EpiPen maker Mylan has finalized a $465 million government agreement settling allegations it overbilled Medicaid for its emergency allergy injectors for a decade — charges brought after rival Sanofi filed a whistleblower lawsuit and tipped off the government.
Mylan, U.S. finalize $465 million EpiPen settlement
Thu, 17 Aug 2017 19:50:50 +0000
Mylan NV (MYL.O) has finalized a $465 million settlement resolving U.S. Justice Department claims it overcharged the government for its EpiPen emergency allergy treatment, which became the center of a firestorm over price increases. The U.S. Attorney's Office in Massachusetts on Thursday announced the accord, which was soon after criticized by some congressional members as being too easy on the drugmaker. It came 10 months after Mylan said it had reached a deal.
Also on Market Tamer…
Follow Us on Facebook